Treatment-resistant depression stories

Jul 31, 2026

MD Anderson researchers identify shared neuroimmune mechanisms in rapid-acting antidepressants

Scientists at The University of Texas MD Anderson Cancer Center have discovered common neuroimmune signatures that may explain how rapid-acting antidepressants like ketamine and psychedelics work to reduce symptoms in treatment-resistant depression.

Jul 31, 20261 source

Jul 7, 2026

Compass Pathways' Psilocybin Therapy Shows Durable Benefits for Treatment-Resistant Depression in Pivotal Trial

Compass Pathways reported results from a pivotal study showing its psilocybin-based therapy demonstrated long-lasting benefits for treatment-resistant depression, though investor reaction was mixed as shares fell nearly 10% on the data.

Jul 7, 20262 sources